GlassScriptPhysician profile
Alexandra K Marques
NPI 1407585060
$14,208.42
in general payments reported to CMS, 2019-2025
41 companies · $4,212 in 2025
The $4,212 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,214 · 2023: $3,779 · 2024: $5,003 · 2025: $4,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,799.68 |
| Education | $195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,960.19 | 2022-2025 | |
| Ucb, INC. | $1,613.29 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $1,301.80 | 2022-2025 | |
| Argenx US, INC. | $937.11 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $788.85 | 2022-2025 | Vyepti |
| Eisai INC. | $711.59 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $689.01 | 2022-2025 | Rytary, Crexont, Lyvispah |
| Teva Pharmaceuticals USA, INC. | $657.74 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $648.02 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $628.69 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $566.79 | 2023-2025 | Nuplazid |
| Genentech USA, INC. | $424.96 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Lilly USA, LLC | $416.67 | 2022-2025 | Kisunla, Amyvid |
| Emd Serono, INC. | $355.36 | 2022-2025 | Mavenclad |
| Celgene Corporation | $265.03 | 2022-2025 | Zeposia |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $262.71 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $229.54 | 2023-2025 | Uplizna, Aimovig |
| Corium, LLC | $152.85 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $151.50 | 2025 | Qelbree |
| Genzyme Corporation | $143.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $125.76 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $120.02 | 2022 | |
| Avion Pharmaceuticals | $113.48 | 2022-2023 | Dhivy |
| Axsome Therapeutics, INC. | $110.24 | 2025 | Symbravo |
| Tris Pharma INC | $108.01 | 2024-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $99.27 | 2023-2024 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $98.32 | 2023-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $86.95 | 2022 | |
| Octapharma USA, INC. | $63.35 | 2023-2024 | Panzyga |
| Vertical Pharmaceuticals, LLC | $58.46 | 2024-2025 | Relexxii |
| Impel Pharmaceuticals INC. | $45.29 | 2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $44.25 | 2023 | Quviviq |
| Tanabe Pharma America, INC. | $38.11 | 2024-2025 | Radicava |
| Neurelis, INC. | $37.63 | 2024-2025 | Valtoco |
| Impel Pharmaceuticals LLC | $35.96 | 2024-2025 | Trudhesa |
| Upsher-Smith Laboratories LLC | $26.40 | 2023 | |
| Csl Behring | $19.16 | 2025 | Hizentra |
| Cycle Pharmaceuticals INC | $18.42 | 2025 | Tascenso Odt, Bafiertam |
| Ironshore Pharmaceuticals INC. | $18.31 | 2023 | Jornay Pm |
| Kyowa Kirin, INC. | $18.13 | 2023 | Nourianz |
| Mdd US Operations, LLC | $17.58 | 2024 | Gocovri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Marques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.